Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA‐based or adenoviral vector‐based SARS‐CoV‐2 vaccination

Kreuter, Alexander; Licciardi-Fernandez, M. J.; Burmann, Sven‐Niklas; Burkert, Beate; Oellig, Frank; Michalowitz, Alena‐Lioba

doi:10.1111/ced.14858

Cited by 45 publications

(51 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of the total papers, eleven articles were from Asia [ 19 , 22 , 25 , 30 , 32 , 33 , 36 , 39 , 41 , 43 , 44 ], eight from Europe [ 15 , 17 , 18 , 20 , 24 , 27 , 38 , 45 ], eleven from North America [ 14 , 16 , 26 , 28 , 29 , 34 , 35 , 37 , 40 , 42 , 46 ], two from South America [ 21 , 31 ] and one from Africa [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient

Ali¹,

Almas²,

Zaidi³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient

Ali¹,

Almas²,

Zaidi³

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

“…The worsening of SCLE with the enlargement of pre-existing plaques on the trunk and emergence of new lesions has been observed in a 50-year-old woman with positive SARS-CoV-2 PCR (26). In addition, cases of Rowell syndrome and SCLE have been reported after COVID-19 vaccines but only a few reports incriminate the infection itself as a potential exacerbating factor (27)(28)(29)(30). Based on the clinical course of the disease, we suggest that the observed Rowell syndrome-like flare-up of CLE was related to the COVID-19 infection in our patient.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection

2022

View full text Add to dashboard Cite

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an important impact on dermatology practice, posing diagnostic and therapeutic challenges especially in patients with inflammatory and autoimmune skin disorders. Disease-specific and nonspecific cutaneous manifestations have been increasingly reported in the spectrum of COVID-19 but the influence of the infection on pre-existing dermatologic diseases has not been clearly defined. There has been a debate in the literature as to whether patients suffering from autoimmune dermatoses, including cutaneous lupus erythematosus (CLE), are at increased risk of SARS-CoV-2 infection, as well as if they experience worsening of their lupus erythematosus (LE)-related clinical symptoms. This article reports on a case of Rowell syndrome occurring after COVID-19 in a 67-year old woman with pre-existing chronic CLE manifesting with few discoid lesions on the face, scalp, and upper chest, successfully controlled with topical corticosteroids and photoprotection. Erythema multiforme (EM)-like eruption developed approximately two weeks after the SARS-CoV-2 infection, the latter being confirmed by positive nasopharyngeal swab and successfully treated with systemic antibiotics and antiaggregants. Diffuse hair loss and patches of cicatricial alopecia were also present upon scalp examination. Laboratory workup, including routine tests, histologic, immunofluorescent, and serologic investigations, was supportive to the diagnosis. Administration of topical and systemic corticosteroids along with peroral hydroxychloroquine resulted in the progressive improvement of the cutaneous lesions. Rowell syndrome is a rare entity in the spectrum of LE, characterized by EM-like lesions, photosensitivity, and positive antinuclear and anti-Ro antibodies, that is currently considered to be a variant of subacute CLE (SCLE). Several cases of SCLE have been described in association with medications, including anti-SARS-CoV-2 vaccines but only a few reports incriminate the infection itself as a potential exacerbating factor. Based on the clinical course of the disease, we suggest that the observed Rowell syndrome-like flare of CLE was related to the COVID-19 infection in this patient.

show abstract

“…9 As both cutaneous lupus erythematosus is regarded as interferon-driven and COVID-mRNA vaccine effects are mediated by interferon I, a relation of both is evident, and the induction of CLE, especially in the context of SLE, may be expected. While an exacerbation of pre-existing SCLE after mRNA vaccination has lately been reported, 10,11 the new onset of SCLE after COVID-19 vaccination has not been described in A 65-year-old-woman presented to our outpatient clinic 2 months after the second injection of ChAdOx1 nCoV-19 vaccine for a 5-month history of itchy eruption. The lesions started ten days after the first injection and worsened seven days after the second, given 3 months apart.…”

Section: Scle Manifestation After Mrna Covid-19 Vaccinationmentioning

confidence: 98%

SCLE manifestation after mRNA COVID‐19 vaccination

Rechtien

Erfurt‐Berge

Sticherling

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA‐based or adenoviral vector‐based SARS‐CoV‐2 vaccination

Cited by 45 publications

References 7 publications

A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient

A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient

Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection

SCLE manifestation after mRNA COVID‐19 vaccination

Contact Info

Product

Resources

About